Details of the Drug

General Information of Drug (ID: DMS1GYT)

Drug Name

Mirabegron

Synonyms

Myrbetriq (TN)

Indication

Disease Entry	ICD 11	Status	REF
Overactive bladder	GC50.0	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

396.5

Topological Polar Surface Area (xlogp)

2.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3.5 h [3]
Bioavailability: The bioavailability of drug is 29% [3]
Clearance: The renal clearance of drug is 13 L/h [3]
Elimination: Of a 160mg radiolabeled dose administered to healthy volunteers, approximately 55% of the radioactivity was recovered in the urine and 34% in the feces [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 26 - 31 hours [3]
Unbound Fraction: The unbound fraction of drug in plasma is 0.29% [4]
Vd: The volume of distribution (Vd) of drug is 1670 L [3]

Chemical Identifiers

Formula: C21H24N4O2S
IUPAC Name: 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
Canonical SMILES: C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
InChI: InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
InChIKey: PBAPPPCECJKMCM-IBGZPJMESA-N

Cross-matching ID

PubChem CID: 9865528
ChEBI ID: CHEBI:65349
CAS Number: 223673-61-8
DrugBank ID: DB08893
TTD ID: D0X5UN
VARIDT ID: DR00699
INTEDE ID: DR1097
ACDINA ID: D01254

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-3 (ADRB3)	TTMXGCW	ADRB3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Overactive bladder

ICD Disease Classification

GC50.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor beta-3 (ADRB3)	DTT	ADRB3	7.81E-01	0.02	0.16
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mirabegron (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Minor	Increased metabolism of Mirabegron caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[33]
Arn-509	DMT81LZ	Minor	Increased metabolism of Mirabegron caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[33]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Mirabegron caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[34]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Mirabegron due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[35]
Pexidartinib	DMS2J0Z	Minor	Increased metabolism of Mirabegron caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[33]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Mirabegron due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[36]
Tucatinib	DMBESUA	Minor	Decreased metabolism of Mirabegron caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[33]
Palbociclib	DMD7L94	Minor	Decreased metabolism of Mirabegron caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[33]
PF-04449913	DMSB068	Moderate	Decreased clearance of Mirabegron due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[37]
Osilodrostat	DMIJC9X	Minor	Decreased metabolism of Mirabegron caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[33]
MK-8228	DMOB58Q	Minor	Decreased metabolism of Mirabegron caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[33]
OPC-34712	DMHG57U	Major	Decreased metabolism of Mirabegron caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[38]
Stiripentol	DMMSDOY	Minor	Decreased metabolism of Mirabegron caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Tazemetostat	DMWP1BH	Minor	Increased metabolism of Mirabegron caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[33]
Cobicistat	DM6L4H2	Minor	Decreased metabolism of Mirabegron caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Mirabegron due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[39]
Suvorexant	DM0E6S3	Minor	Decreased metabolism of Mirabegron caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[33]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Mirabegron caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[37]
Ceritinib	DMB920Z	Minor	Decreased metabolism of Mirabegron caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[33]
PF-06463922	DMKM7EW	Minor	Increased metabolism of Mirabegron caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[33]
Selpercatinib	DMZR15V	Minor	Decreased metabolism of Mirabegron caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[33]
Idelalisib	DM602WT	Minor	Decreased metabolism of Mirabegron caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[33]
GDC-0199	DMH0QKA	Major	Decreased clearance of Mirabegron due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[40]
IPI-145	DMWA24P	Minor	Decreased metabolism of Mirabegron caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[33]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Mirabegron due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[40]
Dabrafenib	DMX6OE3	Minor	Increased metabolism of Mirabegron caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[33]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Mirabegron due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[41]
Fedratinib	DM4ZBK6	Minor	Decreased metabolism of Mirabegron caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[33]
Netupitant	DMEKAYI	Minor	Decreased metabolism of Mirabegron caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[33]
Entrectinib	DMMPTLH	Minor	Decreased metabolism of Mirabegron caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[33]
Rucaparib	DM9PVX8	Minor	Decreased metabolism of Mirabegron caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[33]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Mirabegron caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[42]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Mirabegron caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[33]
Enzalutamide	DMGL19D	Minor	Increased metabolism of Mirabegron caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[33]
Voxelotor	DMCS6M5	Minor	Decreased metabolism of Mirabegron caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[33]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Mirabegron caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[37]
Larotrectinib	DM26CQR	Minor	Decreased metabolism of Mirabegron caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[33]
LEE011	DMMX75K	Minor	Decreased metabolism of Mirabegron caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[33]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Mirabegron caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[43]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Mirabegron due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[44]
Elagolix	DMB2C0E	Minor	Increased metabolism of Mirabegron caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[33]
-----------


⏷ Show the Full List of 41 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acesulfame	E00341	36573	Flavoring agent
Butylated hydroxytoluene	E00336	31404	Antioxidant
Hydrochloric acid	E00015	313	Acidulant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben	E00149	7456	Antimicrobial preservative
Ethylparaben	E00177	8434	Antimicrobial preservative
Simethicone	E00575	6433516	Antifoaming agent; Diluent; Water-repelling agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Haematite red	E00236	14833	Colorant
Xanthan gum	E00694	Not Available	Bioadhesive material; Emulsifying agent; Gelling agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
--------------------


⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Mirabegron 8mg/ml extended release for suspension	8mg/ml	Extended Release For Suspension	Oral
Mirabegron 25mg extended release tablet	25mg	Extended Release Tablet	Oral
Mirabegron 50mg extended release tablet	50mg	Extended Release Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7445).
2	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3	FDA Approved Drug Products: Myrbetriq (mirabegron) extended-release tablets/granules for oral use
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
6	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
7	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
8	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
9	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
10	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
11	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
12	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
13	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
14	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
16	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
17	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
18	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
19	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
20	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
21	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
22	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
23	Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
24	Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
25	Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
26	Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
27	Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
28	Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
29	Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
30	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
31	FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
32	Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49.
33	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
34	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
35	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
36	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
37	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
39	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
40	Cerner Multum, Inc. "Australian Product Information.".
41	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
42	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
43	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
44	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".